FRI0367 ADALIMUMAB IS MORE EFFECTIVE THAN ETANERCEPT AT PREVENTING TNF-ENHANCED OSTEOCLAST DEVELOPMENT THROUGH DOWNREGULATION OF PRO-OSTEOCLASTOGENIC FACTORS ICAM-1 AND IGFBP2 AND UPREGULATION OF ANTI-OSTEOCLASTOGENIC FACTOR FABP4
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.2036
Abstract: Background: TNF has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF and RANKL. We have previously demonstrated that TNF enhances the kinetics of RANKL-induced human osteoclastogenesis and that its effects are… read more here.
Keywords: tnf; ada tnf; pro osteoclastogenic; abbvie inc ... See more keywords
Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134582
Abstract: Background: Improved therapeutic strategies for patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) remain an unmet need. Venetoclax (Ven), a potent, highly selective, oral B-cell lymphoma 2 (BCL-2) inhibitor, and navitoclax… read more here.
Keywords: research; abbvie inc; speakers bureau; research funding ... See more keywords
First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-139923
Abstract: Background: The outcome of elderly patients with Acute Myeloid Leukemia (AML) is poor and treatment options in these high-risk groups are limited. Recently, venetoclax combinations with hypomethylating agents or low dose cytarabine were approved to… read more here.
Keywords: consultancy honoraria; venetoclax based; abbvie inc; research funding ... See more keywords
Lifetime Costs of Patients with Chronic Lymphocytic Leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.5621.5621
Abstract: Introduction: Patients with genomic aberrations del(11q), del(17p), and mutated IGHV in chronic lymphocytic leukemia (CLL) are at the highest risk for poor outcomes including shorter time to initial treatment, non-response to therapy (refractory disease), relapse,… read more here.
Keywords: response; lifetime costs; abbvie inc; economics ... See more keywords